ethyl 3-(1,3-benzodioxol-5-yl)-4-[3-[2-(1-methyl-3,4-dihydro-2H-pyrido[2,3-b]pyrazin-6-yl)ethoxy]-1,2-oxazol-5-yl]butanoate | 724771-52-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: ethyl 3-(1,3-benzodioxol-5-yl)-4-[3-[2-(1-methyl-3,4-dihydro-2H-pyrido[2,3-b]pyrazin-6-yl)ethoxy]-1,2-oxazol-5-yl]butanoate
• CAS: 724771-52-2
• 化学式: C₂₆H₃₀N₄O₆
• 分子量: 494.547
• InChiKey: JUTAGTKMKMIOOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  ethyl 3-(1,3-benzodioxol-5-yl)-4-[3-[2-(1-methyl-3,4-dihydro-2H-pyrido[2,3-b]pyrazin-6-yl)ethoxy]-1,2-oxazol-5-yl]butanoate 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 3-(Benzo[d][1,3]dioxol-5-yl)-4-(3-(2-(1-methyl-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl)ethoxy)isoxazol-5-yl)butanoic acid
  参考文献：
  名称：

  Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists

  摘要：

  We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.045
• 作为产物：
  描述：

  3-(1,3-benzodioxol-5-yl)-7-ethoxy-5,7-dioxoheptanoic acid 在 盐酸 、 sodium hydroxide 、 盐酸羟胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 ethyl 3-(1,3-benzodioxol-5-yl)-4-[3-[2-(1-methyl-3,4-dihydro-2H-pyrido[2,3-b]pyrazin-6-yl)ethoxy]-1,2-oxazol-5-yl]butanoate
  参考文献：
  名称：

  Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists

  摘要：

  We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.045

文献信息

• Heteroarylalkanoic acids as integrin receptor antagonists derivatives
  申请人：Boys L. Mark

  公开号：US20050043344A1

  公开（公告）日：2005-02-24

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the α V β 3 and/or the α V β 5 integrin without significantly inhibiting the α V β 6 integrin.

  本发明涉及包含式I的化合物或其药学上可接受的盐的制药组合物，以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素的方法，而不显著抑制αVβ6整合素。
• HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Pharmacia Corporation

  公开号：EP1592421A1

  公开（公告）日：2005-11-09
• [EN] HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS<br/>[FR] ACIDES HETEROARYLALCANOIQUES EN TANT QU'ANTAGONISTES DU RECEPTEUR D'INTEGRINE
  申请人：PHARMACIA CORP

  公开号：WO2004058254A1

  公开（公告）日：2004-07-15

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the ανβ3 and/or the ανβ5 integrin without significantly inhibiting the ανβ6 integrin.